Pancreatic Cancer Research

ResearcherNantong UniversityNo recent work listed

Ying Xiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6855-0207; OpenAlex author ID A5100356357. Sources: OpenAlex.

Their work

Papers
25 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 5 papers · 2020: 6 papers · 2021: 2 papers · 2022: 4 papers · 2023: 1 paper

Papers 25

  1. Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-023-02499-1↗
  2. Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-022-02203-9↗
  3. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Co-author DOI 10.1016/j.biopha.2022.112713↗
  4. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. First author DOI 10.1038/s41419-022-04799-5↗
  5. Nodal Enhances Perineural Invasion in Pancreatic Cancer by Promoting Tumor-Nerve Convergence. Co-author DOI 10.1155/2022/9658890↗
  6. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  7. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Co-author DOI 10.3389/fonc.2021.728583↗
  8. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  9. Huaier extract restrains pancreatic cancer by suppressing Wnt/β-catenin pathway. Co-author DOI 10.1016/j.biopha.2020.110126↗
  10. Sonic hedgehog signaling pathway promotes pancreatic cancer pain via nerve growth factor. Co-author DOI 10.1136/rapm-2019-100991↗
  11. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  12. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01038↗
  13. Upregulation of exosomal microRNA‑21 in pancreatic stellate cells promotes pancreatic cancer cell migration and enhances Ras/ERK pathway activity. Co-author DOI 10.3892/ijo.2020.4986↗
  14. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… Co-author DOI 10.1002/1878-0261.12399↗
  15. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Co-author DOI 10.1016/j.canlet.2019.07.015↗
  16. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. Co-author DOI 10.1016/j.csbj.2019.03.016↗
  17. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway. Co-author DOI 10.1111/jcmm.14167↗
  18. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway. Co-author DOI 10.1177/0963689719851772↗
  19. Retraction: PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation. Co-author DOI 10.18632/oncotarget.25033↗
  20. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. Co-author DOI 10.3892/ijo.2018.4573↗
  21. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. Co-author DOI 10.3892/or.2018.6518↗
  22. PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation. Co-author DOI 10.18632/oncotarget.20552↗
  23. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression. Co-author DOI 10.1016/j.canlet.2016.01.026↗
  24. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.humpath.2016.07.015↗
  25. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis. First author DOI 10.1016/j.yexmp.2016.08.001↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 17 shared papers, 2018–2023 · strength 1.97
  2. Weikun Qian · 13 shared papers, 2018–2022 · strength 1.40
  3. Tao Qin · 11 shared papers, 2018–2022 · strength 1.24
  4. Jiguang Ma · 11 shared papers, 2018–2022 · strength 1.15
  5. Zheng Wang · 7 shared papers, 2019–2023 · strength 0.94
  6. Wanxing Duan · 7 shared papers, 2018–2022 · strength 0.72
  7. Jie Li · 6 shared papers, 2019–2021 · strength 0.61
  8. Tao Qin · 5 shared papers, 2018–2022 · strength 0.51
  9. Cancan Zhou · 5 shared papers, 2018–2021 · strength 0.48
  10. Zheng Wu · 4 shared papers, 2019–2022 · strength 0.45
  11. Liang Han · 4 shared papers, 2019–2021 · strength 0.42
  12. Tonghua Liu · 4 shared papers, 2017–2020 · strength 0.39
  13. Qiang Ma · 4 shared papers, 2017–2020 · strength 0.39
  14. Huanwen Wu · 4 shared papers, 2017–2020 · strength 0.39
  15. Zhiyong Liang · 4 shared papers, 2017–2020 · strength 0.39
  16. Erxi Wu · 3 shared papers, 2020–2022 · strength 0.36
  17. Liang Han · 3 shared papers, 2018–2022 · strength 0.35
  18. Liang Cheng · 4 shared papers, 2018–2020 · strength 0.35
  19. Guotai Wang · 2 shared papers, 2022–2023 · strength 0.34
  20. He Jiang · 2 shared papers, 2022–2023 · strength 0.34
  21. Jingtao Gu · 2 shared papers, 2022–2023 · strength 0.34
  22. Ke Chen · 3 shared papers, 2019–2022 · strength 0.34
  23. Junyu Cao · 4 shared papers, 2018–2019 · strength 0.33
  24. Yangyang Yue · 3 shared papers, 2020–2021 · strength 0.33
  25. Jianjun Lei · 3 shared papers, 2019–2021 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.